Meta-analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne - 24/04/13
Reprint requests: Alexandra B. Kimball, MD, MPH, 50 Staniford St, Suite 240, Boston, MA 02139.Abstract |
Background |
Comparative efficacy of the multiple treatments containing benzoyl peroxide (BPO) and clindamycin (CL) is not established.
Objective |
We compared the efficacy of topical 5% BPO, 1% to 1.2% CL, 5% BPO with salicylic acid (SA) preparation, and combination BPO/CL in acne lesion reduction.
Methods |
A meta-analysis was conducted using the Cochrane collaboration guidelines in accordance with the PRISMA statement.
Results |
A total of 23 studies including 7309 patients were used in the meta-analysis. At 2 to 4 weeks, 5% BPO + SA had statistically greater percent lesion reductions over other groups (weighted mean inflammatory lesion reduction: BPO = 33.4%, CL = 21.5%, BPO + SA = 55.2%, BPO/CL = 40.7%, placebo = 7.3%; weighted mean noninflammatory lesion reduction: BPO = 19.1%, CL = 10.0%, BPO + SA = 42.7%, BPO/CL = 26.2%, placebo = 6.7%). At 10- to 12-week end points, 5% BPO + SA and BPO/CL were similar, with overlapping confidence intervals (weighted mean inflammatory lesion reduction: BPO = 43.7%, CL = 45.9%, BPO + SA = 51.8%, BPO/CL = 55.6%, placebo = 26.8%; weighted mean noninflammatory lesion reduction: BPO = 30.9%, CL = 32.6%, BPO + SA = 47.8%, BPO/CL = 40.3%, placebo = 17.0%).
Limitations |
Trial heterogeneity, publication bias, and deficits in the reporting of individual primary studies may affect results.
Conclusion |
At early time points, 5% BPO + SA had the best profile. BPO/CL was only incrementally better than BPO alone but was superior to CL alone. At later time points, 5% BPO + SA was similar to BPO/CL.
Le texte complet de cet article est disponible en PDF.Key words : acne vulgaris, benzoyl peroxide, clindamycin, combination benzoyl peroxide/clindamycin, meta-analysis, salicylic acid
Abbreviations used : BPO, CL, FDA, SA
Plan
| Supported by Obagi Medical Products Inc. |
|
| Conflicts of interest: None declared. |
|
| Disclosure: Dr Kimball has been a consultant for Obagi and for Arcutis; she is currently an investigator for Stiefel and consultant for Galderma. Ms Seidler has no conflicts of interest to declare. |
Vol 63 - N° 1
P. 52-62 - juillet 2010 Retour au numéro
Article précédent
- Reactive nonsexually related acute genital ulcers: Review of cases evaluated at Mayo Clinic
- Julia S. Lehman, Alison J. Bruce, David A. Wetter, Sara B. Ferguson, Roy S. Rogers
- Enacting legislation to restrict youth access to tanning beds: A survey of advocates and sponsoring legislators
- Busayo Obayan, Alan C. Geller, Elissa A. Resnick, Marie-France Demierre
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?